ABUS

Over the past six months, Arbutus received U.S. FDA Fast Track Designation for Imdusiran, reported its Fourth Quarter and Year End 2025 Financial Results, announced a $2.25 billion global settlement with Moderna, reported its Third Quarter 2025 Financial Results, and announced that four abstracts were accepted for presentation at AASLD - The Liver Meeting® 2025. The stock has experienced a 34.650% change over the past year, with a 52-week range between $2.94 and $5.10. As of May 8, 2026, the stock traded at $4.35, within a 52-week range of $3.08 to $4.95.